Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "IPO"

141 News Found

Indian Pharmaceutical Market reports slower growth in October
News | November 26, 2021

Indian Pharmaceutical Market reports slower growth in October

Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins


Lupin launches fenofibrate in the US
Drug Approval | November 08, 2021

Lupin launches fenofibrate in the US

The drug helps in managing cholesterol


Indian Pharma Market witnesses rise in volumes and prices in September.
News | October 28, 2021

Indian Pharma Market witnesses rise in volumes and prices in September.

Acute therapies continue to report strong growth compared to chronic ones.


GPT Healthcare to go public to fund expansion
Hospitals | October 18, 2021

GPT Healthcare to go public to fund expansion

The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India


SecureKloud to list subsidiary Healthcare Triangle on Nasdaq
News | October 13, 2021

SecureKloud to list subsidiary Healthcare Triangle on Nasdaq

The company plans to raise US $ 15 million


Wellness Forever files DRHP to raise Rs 1500-1600 crore
Startup | October 04, 2021

Wellness Forever files DRHP to raise Rs 1500-1600 crore

Its store network grew from 144 stores in March 2019 to 236 stores. It has a presence in 23 cities across Maharashtra, Goa and Karnataka, employing more than 4,600 people.


Global Health files DRHP for over Rs 500 crore issue
News | October 01, 2021

Global Health files DRHP for over Rs 500 crore issue

Global Health operates a network of four hospitals under the Medanta brand in Gurugram, Indore, Ranchi and Lucknow. In addition, one hospital is under construction in Patna, and another is planned for development in Noida


U.S. FDA approves Repatha for paediatric patients aged 10 years and older
Drug Approval | September 27, 2021

U.S. FDA approves Repatha for paediatric patients aged 10 years and older

The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients


Acute therapies drive overall pharma growth in July: Ind-Ra
News | August 30, 2021

Acute therapies drive overall pharma growth in July: Ind-Ra

The segment delivered strong sales growth of 20% YoY


U.S. FDA approves drug-free VNS system for stroke
Drug Approval | August 28, 2021

U.S. FDA approves drug-free VNS system for stroke

When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke